Núcleo Acadêmico de Estudos e Pesquisas em Biotecnologia e Biologia Molecular (NAPBBM) - Centro Universitário Lusíada (UNILUS), Rua Oswaldo Cruz, 179 - Boqueirão, Santos - São Paulo, 11015-300, Brazil.
Grupo Oncoclínicas, São Paulo, Brasil.
Immunotherapy. 2022 Mar;14(4):249-257. doi: 10.2217/imt-2021-0175. Epub 2022 Jan 25.
Immune checkpoint inhibitors improved the overall survival of patients with advanced non-small-cell lung cancer and changed the treatment since the last decade. The duration of response is longer than what is seen with chemotherapy or targeted agents; however, some patients have no benefit or even a progressive disease as best response. Immune checkpoint inhibitor plus chemotherapy combinations are a very useful strategy, but defining precisely who will benefit most from immunotherapy is still a main question. Therefore, understanding the genetics of the tumor microenvironment is a way to determine new predictive biomarkers to replace the only one currently accepted, PD-L1 expression, whose application is surrounded by uncertainties.
免疫检查点抑制剂改善了晚期非小细胞肺癌患者的总体生存率，并改变了过去十年的治疗方法。与化疗或靶向药物相比，其反应持续时间更长；然而，一些患者没有受益，甚至对最佳反应产生进行性疾病。免疫检查点抑制剂联合化疗是一种非常有用的策略，但明确谁将从免疫治疗中获益最多仍然是一个主要问题。因此，了解肿瘤微环境的遗传学是确定新的预测生物标志物的一种方法，以替代目前唯一被接受的 PD-L1 表达，其应用存在诸多不确定性。
